MIRM: Pivotal data and regulatory milestones across rare diseases set the stage for significant growth
Upcoming quarters will see pivotal data readouts for HDV, cholestatic pruritus, and FOP, with regulatory submissions and potential label expansions planned for next year. Market opportunities are expanding through improved patient identification and differentiated therapies, while AI integration is…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.